Gill looks to enhance Scoping Study metrics at Mt Carrington


Published 17-JAN-2017 15:40 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Chief Executive of White Rock Minerals (ASX:WRM), Matt Gill, announced on Tuesday morning that the company was ready to embark on what could be a transformational journey for the group as it undertakes a revised Scoping Study and moves towards a Definitive Feasibility Study (DFS) at its Mt Carrington gold/silver project located in north-eastern New South Wales.

Gill has an established reputation for transforming small early stage mining projects into robust going concerns with some of the previous companies he has been at the helm of being the subject of takeovers following successful development.

Of course, WRM is still in its early stages and similar events may not occur, so when looking at investing in this stock seek professional financial advice.

As Gill prepares to guide the project through a revised Scoping Study process, leading to a Definitive Feasibility Study he also highlighted the already impressive aspects of the previously conducted Scoping Study in saying, “The potential uplift of a revised Scoping Study would further enhance the strong financial metrics of the project where the current project Scoping Study results already imply an outstanding investment proposition with a pre-tax NPV10 of $60.6 million and an internal rate of return of more than 100%, with $100 million in free cash (undiscounted and before financing) delivered over the initial seven year mine life”.

Mt Carrington currently has a JORC resource of 338,000 ounces of gold and 23.4 ounces of silver, but Gill highlighted the significant potential upside for expanding the in pit mineral resource which could then flow through to increased mine life and/or higher gold and silver production rates.

While the Scoping Study, was conducted in mid-2012 the implied Australian dollar gold price was in line with today’s spot price taking into account foreign exchange rate movements.

Having substantial infrastructure in place from previous mine site work would benefit White Rock should it be able to bring the project into production.

Having raised $4.9 million before costs late last year and negotiated future financing for the construction and commissioning of the Mt Carrington project with repayments to be made from a percentage of future gold and silver production, the project has been substantially de-risked.

Furthermore, this should alleviate the need to conduct dilutive capital raisings that involve the issue of new shares. In commenting on the WRM’s financial position, Gill noted, “The funding proposal will directly provide for construction and commissioning through to commercial production, subject to the successful delivery of the Definitive Feasibility Study.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free